Caption Management’s Aclaris Therapeutics ACRS Stock Holding History

Caption Management’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,000	Closed	-$57K	–	1449
2024 Q4	$57K	Buy	+23,000	New	+$57.2K	﹤0.01%	1358
2023 Q4	–	Sell	-453,000	Closed	-$3.1M	–	1295
2023 Q3	$3.1M	Buy	453,000 +442,900	+4,385%	+$3.78M	0.05%	469
2023 Q2	$105K	Sell	10,100 -23,100	-70%	-$209K	﹤0.01%	978
2023 Q1	$269K	Buy	+33,200	New	+$421K	0.01%	892
2021 Q3	–	Sell	-33,300	Closed	-$585K	–	1461
2021 Q2	$585K	Buy	+33,300	New	+$756K	0.01%	1008

Other funds holding ACRS

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caption Management's ACRS Position: Q1 2025 in Review

Caption Management sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 17,960 shares — an estimated $44.5K sold.

Caption Management first reported a position in ACRS in Q1 2023 and held it in 5 quarters. The position peaked at $1.79M in Q1 2023. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

Caption Management reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
Caption Management sold 17,960 Aclaris Therapeutics shares in Q1 2025, an estimated $44.5K.
Caption Management first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 5 quarters.
Caption Management's Aclaris Therapeutics position peaked at $1.79M in Q1 2023.
109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.